Recognition of Class II MHC Peptide Ligands That Contain β-Amino Acids
暂无分享,去创建一个
J. Sidney | A. Sette | H. Ploegh | S. Gellman | Ross W. Cheloha | Djenet Bousbaine | Shi Liu | Andrew W. Woodham | Tong Wang
[1] S. Gellman,et al. Receptor selectivity from minimal backbone modification of a polypeptide agonist , 2018, Proceedings of the National Academy of Sciences.
[2] H. Ploegh,et al. Nanobody–Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses , 2018, Cancer Immunology Research.
[3] H. Ploegh,et al. Targeted antigen delivery by an anti-class II MHC VHH elicits focused αMUC1(Tn) immunity† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc00446j Click here for additional data file. , 2017, Chemical science.
[4] H. Ploegh,et al. Generation of Immunity against Pathogens via Single-Domain Antibody–Antigen Constructs , 2016, The Journal of Immunology.
[5] P. Sexton,et al. β-Arrestin-Biased Agonists of the GLP-1 Receptor from β-Amino Acid Residue Incorporation into GLP-1 Analogues. , 2016, Journal of the American Chemical Society.
[6] S. Gellman,et al. Targeting recognition surfaces on natural proteins with peptidic foldamers. , 2016, Current opinion in structural biology.
[7] Allison S. Walker,et al. In Vivo Biosynthesis of a β-Amino Acid-Containing Protein. , 2016, Journal of the American Chemical Society.
[8] W. S. Horne,et al. Peptide Backbone Composition and Protease Susceptibility: Impact of Modification Type, Position, and Tandem Substitution , 2016, Chembiochem : a European journal of chemical biology.
[9] S. Gellman,et al. Targeting diverse protein–protein interaction interfaces with α/β-peptides derived from the Z-domain scaffold , 2015, Proceedings of the National Academy of Sciences.
[10] J. Sidney,et al. Consequences of Periodic α-to-β3 Residue Replacement for Immunological Recognition of Peptide Epitopes , 2015, ACS chemical biology.
[11] D. D. Da Silva,et al. Functional analysis of HPV-like particle-activated Langerhans cells in vitro. , 2015, Methods in molecular biology.
[12] P. Perlmutter,et al. Single β3-amino acid substitutions to MOG peptides suppress the development of experimental autoimmune encephalomyelitis , 2014, Journal of Neuroimmunology.
[13] A. Saghatelian,et al. A Potent α/β-Peptide Analogue of GLP-1 with Prolonged Action in Vivo , 2014, Journal of the American Chemical Society.
[14] S. Gellman,et al. Backbone modification of a polypeptide drug alters duration of action in vivo , 2014, Nature Biotechnology.
[15] Carla P. Guimarães,et al. Site-specific C-terminal and internal loop labeling of proteins using sortase-mediated reactions , 2013, Nature Protocols.
[16] Peter Cresswell,et al. Pathways of antigen processing. , 2013, Annual review of immunology.
[17] Clemencia Pinilla,et al. Measurement of MHC/Peptide Interactions by Gel Filtration or Monoclonal Antibody Capture , 2013, Current protocols in immunology.
[18] S. Gellman,et al. NINETEEN a-Helix Mimicry with a / b-Peptides , 2013 .
[19] S. Gellman,et al. α-Helix mimicry with α/β-peptides. , 2013, Methods in enzymology.
[20] L. Stern,et al. Conformational variation in structures of classical and non‐classical MHCII proteins and functional implications , 2012, Immunological reviews.
[21] J. Maynard,et al. Flanking Residues Are Central to DO11.10 T Cell Hybridoma Stimulation by Ovalbumin 323–339 , 2012, PloS one.
[22] W Seth Horne,et al. Peptide and peptoid foldamers in medicinal chemistry , 2011, Expert opinion on drug discovery.
[23] Ida E. Andersson,et al. (E)-alkene and ethylene isosteres substantially alter the hydrogen-bonding network in class II MHC A(q)/glycopeptide complexes and affect T-cell recognition. , 2011, Journal of the American Chemical Society.
[24] S. Gellman,et al. Broad distribution of energetically important contacts across an extended protein interface. , 2011, Journal of the American Chemical Society.
[25] N. Croft,et al. Peptidomimetics: modifying peptides in the pursuit of better vaccines , 2011, Expert review of vaccines.
[26] Min Lu,et al. Structural and biological mimicry of protein surface recognition by α/β-peptide foldamers , 2009, Proceedings of the National Academy of Sciences.
[27] Robert M. Plenge,et al. Defining the Role of the MHC in Autoimmunity: A Review and Pooled Analysis , 2008, PLoS genetics.
[28] W Seth Horne,et al. Sequence-based design of alpha/beta-peptide foldamers that mimic BH3 domains. , 2008, Angewandte Chemie.
[29] Bjoern Peters,et al. HLA class I supertypes: a revised and updated classification , 2008, BMC Immunology.
[30] H. Gruppen,et al. Prediction of molar extinction coefficients of proteins and peptides using UV absorption of the constituent amino acids at 214 nm to enable quantitative reverse phase high-performance liquid chromatography-mass spectrometry analysis. , 2007, Journal of agricultural and food chemistry.
[31] E. Unanue,et al. The Insulin-Specific T Cells of Nonobese Diabetic Mice Recognize a Weak MHC-Binding Segment in More Than One Form1 , 2007, The Journal of Immunology.
[32] S. Muller,et al. Heteroclitic properties of mixed α-and aza-β3-peptides mimicking a supradominant CD4 T cell epitope presented by nucleosome , 2007 .
[33] S. Muller,et al. Heteroclitic properties of mixed alpha- and aza-beta3-peptides mimicking a supradominant CD4 T cell epitope presented by nucleosome. , 2007, Molecular immunology.
[34] Heinrich Leonhardt,et al. Targeting and tracing antigens in live cells with fluorescent nanobodies , 2006, Nature Methods.
[35] J. McCluskey,et al. T Cell Determinants Incorporating β-Amino Acid Residues Are Protease Resistant and Remain Immunogenic In Vivo1 , 2005, The Journal of Immunology.
[36] A. Sant,et al. Energetics and cooperativity of the hydrogen bonding and anchor interactions that bind peptides to MHC class II protein. , 2005, Journal of molecular biology.
[37] E. Bergseng,et al. Main Chain Hydrogen Bond Interactions in the Binding of Proline-rich Gluten Peptides to the Celiac Disease-associated HLA-DQ2 Molecule* , 2005, Journal of Biological Chemistry.
[38] P. Kast,et al. The Proteolytic Stability of ‘Designed’ β‐Peptides Containing α‐Peptide‐Bond Mimics and of Mixed α,β‐Peptides: Application to the Construction of MHC‐Binding Peptides , 2005 .
[39] M. Wauben,et al. Possibilities and limitations in the rational design of modified peptides for T cell mediated immunotherapy. , 2005, Molecular immunology.
[40] M. Patarroyo,et al. Characterization of a reduced peptide bond analogue of a promiscuous CD4 T cell epitope derived from the Plasmodium falciparum malaria vaccine candidate merozoite surface protein 1. , 2004, Molecular immunology.
[41] P. Perlmutter,et al. β-amino acids: Versatile peptidomimetics , 2002 .
[42] H. Ploegh,et al. Specific role for cathepsin S in the generation of antigenic peptides in vivo , 2002, European journal of immunology.
[43] P. Perlmutter,et al. Beta-amino acids: versatile peptidomimetics. , 2002, Current medicinal chemistry.
[44] A. Sant,et al. Hydrogen Bond Integrity Between MHC Class II Molecules and Bound Peptide Determines the Intracellular Fate of MHC Class II Molecules1 , 2001, The Journal of Immunology.
[45] C. Beeson,et al. Utility of azapeptides as major histocompatibility complex class II protein ligands for T-cell activation. , 2001, Journal of medicinal chemistry.
[46] A. Sant,et al. Energetic asymmetry among hydrogen bonds in MHC class II⋅peptide complexes , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[47] D. Rognan,et al. β-Amino Acid Scan of a Class I Major Histocompatibility Complex-restricted Alloreactive T-cell Epitope* , 2001, The Journal of Biological Chemistry.
[48] J. Briand,et al. Synthesis and antigenic properties of reduced peptide bond analogues of an immunodominant epitope of the melanoma MART‐1 protein , 2001, Journal of peptide science : an official publication of the European Peptide Society.
[49] J. Briand,et al. Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumor-infiltrating lymphocytes. , 2000, Journal of medicinal chemistry.
[50] R Crowther,et al. Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures. , 2000, Journal of medicinal chemistry.
[51] B. Chain,et al. Protein degradation in MHC class II antigen presentation: opportunities for immunomodulation. , 2000, Seminars in Cell and Developmental Biology.
[52] B. Evavold,et al. DO11.10 and OT-II T Cells Recognize a C-Terminal Ovalbumin 323–339 Epitope1 , 2000, The Journal of Immunology.
[53] H. Ploegh,et al. Proteolysis in MHC class II antigen presentation: who's in charge? , 2000, Immunity.
[54] B. Evavold,et al. DO 11 . 10 and OT-II T Cells Recognize a C-Terminal Ovalbumin 323 – 339 Epitope 1 , 2000 .
[55] A. Goldberg,et al. Proteolysis and class I major histocompatibility complex antigen presentation , 1999, Immunological reviews.
[56] P. Kourilsky,et al. Role of peptide backbone in T cell recognition. , 1999, Journal of immunology.
[57] H. Pircher,et al. Protection against Lymphocytic Choriomeningitis Virus Infection Induced by a Reduced Peptide Bond Analogue of the H-2Db-restricted CD8+ T Cell Epitope GP33* , 1999, The Journal of Biological Chemistry.
[58] G. Jung,et al. N‐hydroxy‐amide analogues of MHC‐class I peptide ligands with nanomolar binding affinities , 1998, Journal of peptide science : an official publication of the European Peptide Society.
[59] T. Walk,et al. New Synthetic Non-peptide Ligands for Classical Major Histocompatibility Complex Class I Molecules* , 1998, The Journal of Biological Chemistry.
[60] E. Sercarz,et al. Modulation of the immunogenicity of antigenic determinants by their flanking residues. , 1998, Immunology today.
[61] P. A. Peterson,et al. Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues. , 1998, Immunity.
[62] A. Ménez,et al. Pseudopeptide ligands for MHC II-restricted T cells. , 1998, International immunology.
[63] A Sette,et al. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. , 1997, Journal of molecular biology.
[64] V. Lotteau,et al. Selective increased presentation of type II collagen by leupeptin. , 1997, International immunology.
[65] J. Briand,et al. Exploration of Requirements for Peptidomimetic Immune Recognition , 1996, The Journal of Biological Chemistry.
[66] P. Kourilsky,et al. Efficient Binding of Reduced Peptide Bond Pseudopeptides to Major Histocompatibility Complex Class I Molecule (*) , 1995, The Journal of Biological Chemistry.
[67] S. Diment,et al. Destructive proteolysis by cysteine proteases in antigen presentation of ovalbumin , 1995 .
[68] H. Rammensee,et al. Chemistry of peptides associated with MHC class I and class II molecules. , 1995, Current opinion in immunology.
[69] J. Berg,et al. A comparison of the immunogenicity of a pair of enantiomeric proteins , 1993, Proteins.
[70] K. Rock,et al. Two genetically identical antigen-presenting cell clones display heterogeneity in antigen processing. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[71] Alessandro Sette,et al. Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells , 1987, Nature.
[72] P. Marrack,et al. The major histocompatibility complex-restricted antigen receptor on T cells. , 1984, Annual review of immunology.
[73] P. Marrack,et al. THE MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTED ANTIGEN RECEPTOR ON T CELLS , 2003 .
[74] P. Marrack,et al. Use of I region-restricted, antigen-specific T cell hybridomas to produce idiotypically specific anti-receptor antibodies. , 1983, Journal of immunology.
[75] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.